Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia
Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia
The aim of the study is to setup a collection of maternal plasma and serum from patients with
 preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on
 extra-corporal removal of sFlt-1
A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal
 pregnancy (NP) :

 -  Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP

 -  Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP

 -  Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP

 -  Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP

 -  Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP
Inclusion Criteria:

 -  Age from 18 to 50 years old

 -  Singleton pregnancies between 20 and 41 weeks of gestation

 -  Preeclampsia

 -  Normal pregnancy

 Exclusion Criteria:

 -  Age<18

 -  Infectious disease: HIV, HBV or HCV

 -  Multiple pregnancies

 -  Opposition of the patient